Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Assess the Pharmacokinetics and Safety of Ascending Doses of JOTROL Oral Gelcaps in Healthy Subjects, and to Determine the Influence of Food

Next Previous
Trial Profile

A Phase 1 Study to Assess the Pharmacokinetics and Safety of Ascending Doses of JOTROL Oral Gelcaps in Healthy Subjects, and to Determine the Influence of Food

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Resveratrol (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept

Most Recent Events

  • 23 Jul 2025 According to a Jupiter Orphan Therapeutics media release, results from the trial were published in the Journal of Alzheimers Disease and AAPS Open in February 2022.
  • 13 Jul 2022 Protocol amended as drug concentration changed from 1000mg to 500mg and time frame is from 8 weeks to Pre-dose and 0.133, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, and 32 hours post-dose on Day 1 days in primary results.
  • 13 Jul 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top